Regression effect on diastolic dysfunction with combination of valsartan and amplodipin in the obese patients

WOS: 00027974260103

Importance of metabolic syndrome definitions in prediction of cardiometabolic risk/Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition

WOS: 000254243500027PubMed ID: 1751322

Effects of telmisartan and valsartan on insulin resistance, visfatin and adiponectin levels in hypertensive patients with metabolic syndrome

WOS: 000254637500003Objective. The aims of this study were to compare the effect of telmisartan and valsartan on the blood and insulin sensitivity and adiponectin levels in hypertensive patients with metabolic syndrome. Patients and Methods. One hundred twenty male patients who met the criteria for metabolic syndrome defined as in ATP III enrolled in the sudy. All patients were randomized to receive treatment with telmisartan 80 mg (n=70) or valsartan 160 mg (n=50) once daily for 6 months. Serum insulin concentration was measured by chemiluminescence, plasma levels of adiponectin and visfatin by Enzyme linked immunosorbent assay kit (ELISA). Insulin resistance (IR) was estimated using the homeostasis model assessment (HOMA). Results: Mean HOMA-IR and adiponectin and visfatin levels were measured 3.00 +/- 0.9 and 5.93 +/- 0.3 mgr/ml and 23.45 +/- 6.1 mgr/ml in patients before starting treatment of telmisartan, respectively. They were changed to 2.4 +/- 0.5 and 6.71 +/- 0.5 mg/ml and 21.40 +/- 5.0 mg/ml at a 6 months period. In valsartan group, mean HOMA-IR and adiponectin and visfatin levels were measured 2.9 +/- 0.5 and 5.50 +/- 0.9 mg/ml 19.05 +/- 3.9 mg/ml before treatment, respectively. After a 6 months period, mean HOMA-IR and adiponectin and visfatin levels were found 3.00 +/- 0.9 and 6.24 +/- 0.7 mg/ml and 20.76 +/- 4.5 mg/ml, respectively. Conclusion: Telmisartan produced significant reductions from baseline in HOMA-IR and insulin levels, whereas valsartan did not. Both telmisartan and valsartan did no changed serum visfatin levels but they increased serum adiponectin concentrations by RAS blockade

Benefit effect of valsartan on adhesion molecules in the hypertensive type 2 diabetes mellitus

WOS: 00027333320035

Relationship between 25-hydroxyvitamin D Level and Metabolic Control and Albumin Excretion Rate in Elderly Patients with Type 2 Diabetes Mellitus

The aims of the study were 1. to investigate the frequency of 25-hydroxyvitamin D deficiency and 2. to observe the relationships between D vitamin supplementation for 6 months and albumin excretion in elderly patients with type 2 diabetes mellitus. The study population included 100 patients with type 2 DM treated with insulin therapy (mean age 56.1±8.8 yrs) were enrolled in the study. Of 100 patients, 30 (mean age 65.4±6.4 yrs) had low 25(OH)D level. Patients with low 25(OH)D level received 50,000 unit of vitamin D3 orally per three weeks for 6 months. Albumin excretion rate (AER) was measured in patients with low level 25(OH) D before and after D vitamin supplementation In study group (n= 100), 30 patients had low 25(OH)D level. Concentrations of 25(OH)D were; 10 (33.3%) had insufficient vitamin D levels, 19 (63.4%) had deficient levels, 1 (3.3%) had severe deficiency in patients with deficiency. There were statistically significantly differences for plasma levels of HbA1c (p=0.001), postprandial glucose (p=0.0001), triglyceride (p=0.04), total-Cholesterol (p=0.03), LDL-Cholesterol (p=0.02), and HDL-Cholesterol (p=0.001) between D vitamin supplementation. There were high frequency of 25(OH)D deficiency in patients with type 2 diabetic patients. And also, D vitamin suplementation changed metabolic parameters such as triglyceride, total-Cholesterol, LDL-Cholesterol and HDL-Cholesterol, postprandial glucose and HbA1c levels but not albumin excretion rate. [Med-Science 2013; 2(4.000): 852-62

Medicine Science 2013;2(4):830-41 IRS gene polymorphism in OSAS Original Investigation Lack of Association of Insulin Receptor Substrate Gene Polymorphisms with Obstructive Sleep Apnea Syndrome Medicine Science 2013;2(4):830-41 IRS gene polymorphism in OS

Abstract Sleep apnea syndrome is associated with increased prevalence of diabetes and has recently shown to be associated with insulin resistance. The aim of the present study was to investigate the relationships between insulin resistance, insulin receptor substrate-1 (IRS-1), insulin receptor substrate-2 (IRS-2) gene polymorphisms and obstructive sleep apnea syndrome (OSAS). The study population consisted of 56 consecutive patients with OSAS and 26 subjects without OSAS were enrolled in the study. Genotyping of IRS-1 and IRS-2 were amplified by polymerase chain reaction (PCR). Insulin resistance was estimated using the homeostasis model assessment (HOM

Early menopause association with employment, smoking, divorced marital status and low leptin levels

WOS: 000288979000012PubMed ID: 20528208Aims. The aims of this study were (1) to investigate the determining risk factors related to early menopause and (2) to compare the relationships between demographic characteristics and hormonal status and leptin levels in subjects with early (no surgical) and natural menopause. Study design. The prospective study was conducted on 500 women with early and 2700 women with natural menopause. Detailed information was collected about their employment status, past and present smoking habits, coffee and alcohol use, educational level and other factors relevant to health. Thirty participants with early menopause and 30 participants with natural menopause were evaluated for hormone and leptin levels. Results. Employment status (OR: 1.94), current smoking (OR: 1.80) and divorced marital status (OR: 1.79) were found to be significant risk factors for early menopause. Mean levels of leptin in natural and early menopause were measured 11.40 +/- 4.1 rig/ml and 8.01 +/- 3.9 ng/ml, respectively (p = 0001). Leptin levels in the early (r = 0.765, p = 0.001) and natural (r = 0.750, p = 0.001) menopause subjects correlated positively with oestradiol (E2) levels. Conclusion. This study shows that early onset of menopause is correlated with smoking, employment status, divorced marital status and lower leptin levels

Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and C-reactive protein in obese patients with obstructive sleep apnea syndrome

Objective: The prevalence of obstructive sleep apnea syndrome (OSAS) and metabolic syndrome is increasing worldwide, in part linked to epidemic of obesity. The purposes of this study were to establish the rate of metabolic syndrome and to compare fibrinogen, homocysteine, high-sensitivity C-reactive protein (hsCRP), leptin levels, and homeostasis model assessment insulin resistance (HOMA-IR) in the obese patients with and without OSAS. Methods: The study population included 36 consecutive obese patients with OSAS (23 males; mean age, 50.0 ±19.7 years), and 34 obese patients without OSAS (17 males; mean age, 49.7±11.1 years) were enrolled as control group. Metabolic syndrome was investigated; fibrinogen, homocysteine, CRP, and leptin levels were measured, and IR was assessed. Results: Metabolic syndrome was found in 17 (47.2%) obese OSAS patients, whereas only 29.4% of obese subjects had metabolic syndrome (P > 0.05). Obese patients with OSAS had significantly higher mean levels of triglyceride (P< 0.001), total-cholesterol ( P = 0.003), low-density lipoprotein-cholesterol ( P = 0.001), fasting glucose ( P = 0.01), HOMA-IR ( P<0.001), thyroid-stimulating hormone ( P = 0.03), fibrinogen ( P < 0.003), hsCRP ( P <0.001), and leptin ( P = 0.03) than control group . Besides, leptin level was positively correlated with waist ( r = 0.512, P = 0.03) and neck circumferences ( r = 0.547, P = 0.03), and fasting glucose (r = 0.471, P = 0.04) in OSAS patients, but not in obese subjects. Conclusion: This study demonstrated that obese OSAS patients may have an increased rate of metabolic syndrome and higher levels of serum lipids, fasting glucose, IR, leptin, fibrinogen, and hsCRP than obese subjects without sleep apnea. Thus, clinicians should be encouraged to systematically evaluate the presence of metabolic abnormalities in OSAS and vice versa

Metabolic syndrome and insulin resistance in obese patients with obstructive sleep apnea syndrome

WOS: 00027974260103